Ep 46: Ideaya’s eye cancer drug met its phase 2/3 primary endpoint, clearing a path to accelerated FDA filing later this year.

**HOOK:** Ideaya’s eye cancer drug met its phase 2/3 primary endpoint, clearing a path to accelerated FDA filing later this year. ━━━━━━━━━━━━━━━━━━━━ ### Top 15 Science & Health Discoveries 1. **Eye Cancer Drug Hits Phase 2/3 Goal: 15 Apr 2026 • Fierce Biotech** Ideaya Biosciences and Servier’s candidate has succeeded in its phase 2/3 trial for a form of eye cancer. The result positions the companies to submit for accelerated FDA approval in the second half of 2026. ... AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis (ElevenLabs) for audio production.